Company profile
Elutia Inc
NASDAQ: ELUT · Healthcare · Biotechnology
#610 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
52DFH 74DQ 32GM 34SS 42
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$16.0M
Rev growth YoY (TTM)
-32.6%
Net income (FY)
$53.4M
Employees
26
as of 2026-08-20
Market cap
$40.8M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$12.3M$12.3M2025
Net income$53.4M$53.4M2025
Operating income-$26.9M-$26.9M2025
Total assets$62.4M$62.4M2025
Liabilities$34.7M$34.7M2025
Equity$27.7M$27.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Women's Health74%
Cardiovascular26%
By geography
Not disclosed.
The read
What is Elutia Inc’s revenue?
Elutia Inc booked $12.3M in FY2025 revenue, contracting 50% year over year — slower than 81% of Healthcare companies we track, at a 434.2% net margin.
Peers · Healthcare
Clearday, Inc.——Medical Marijuana, Inc.58CEmmaus Life Sciences, Inc.40DDevonian Health Group Inc.46DPrelude Therapeutics Incorporated37DEscalon Medical Corp.63CNeighbors
Montgomery →Key facts
CEOC. Randal Mills
SectorHealthcare
IndustryBiotechnology
HeadquartersGaithersburg, MD
ExchangeNASDAQ: ELUT
Employees26
IPO date2020-10-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.